BEAM · Beam Therapeutics Inc.

Beam Therapeutics' Q1 2026 results reflect ongoing investment in its precision genetic medicines pipeline, with R&D expenses rising to $104.5 million from $98.8 million year-over-year, driven by clinical advancements across liver-targeted and hematology programs. G&A expenses increased to $34.4 million from $27.9 million, likely supporting commercial preparations. License and collaboration revenue grew significantly to $31.7 million from $7.5 million, partially offsetting higher opex to narrow the net loss to $94.3 million or $0.91 per share from $108.3 million or $1.23 per share. CEO John Evans highlighted BEAM-302's robust AAT increases and well-tolerated safety at doses up to 75 mg, selecting 60 mg as the optimal biological dose based on Phase 1/2 data, with FDA feedback supporting an accelerated approval pathway and pivotal cohort enrollment of ~50 AATD patients starting H2 2026. Risto-cel's BEACON trial data in NEJM demonstrated deep SCD marker resolution, rapid engraftment, and manufacturing predictability, positioning it for potential BLA submission by year-end 2026. BEAM-304 advances base editing to correct PKU mutations via LNP delivery, with IND filing expected in 2026 post pre-IND activities, while BEAM-301 data in GSDIa is due later this year. The $1.2 billion cash position, unchanged from year-end 2025 and bolstered by $100 million closed and $100 million anticipated from Sixth Street financing, provides runway into mid-2029 through risto-cel launch, BEAM-302 pivotal execution, and BEAM-304 proof-of-concept, reducing near-term funding risks amid clinical momentum.